Evidence map›Paper›PMID 33526087›Full record

ArticleResearch involvement and engagement2021

The practice of active patient involvement in rare disease research using ICT: experiences and lessons from the RUDY JAPAN project.

Nao Hamakawa, Atsushi Kogetsu, Moeko Isono, Chisato Yamasaki, Shirou Manabe, Toshihiro Takeda, Kazumasa Iwamoto, Tomoya Kubota, Joe Barrett, Nathanael Gray and 10 more

Open access · goldAbstract read
In one paragraph

Article in Research involvement and engagement, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 3 countries.

Nao Hamakawa *Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Atsushi Kogetsu *Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Moeko IsonoDepartment of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Chisato YamasakiDepartment of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Shirou ManabeDepartment of Medical Informatics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Toshihiro TakedaDepartment of Medical Informatics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Kazumasa IwamotoDepartment of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Tomoya KubotaDepartment of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Joe BarrettNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Nathanael GrayNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Alison TurnerNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Harriet TeareHeLEX Centre, University of Oxford, Oxford, UK.
Yukie Imamura *HAEJ, Non-profit Patient Organization for Hereditary Angioedema in Japan, Kakogawa, Hyogo, Japan.
Beverley Anne Yamamoto *HAEJ, Non-profit Patient Organization for Hereditary Angioedema in Japan, Kakogawa, Hyogo, Japan.
Jane KayeHeLEX Centre, University of Oxford, Oxford, UK.
Michihiro HideDepartment of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Masanori P TakahashiDepartment of Functional Diagnostic Science, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Yasushi MatsumuraDepartment of Medical Informatics, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Muhammad Kassim JavaidNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Kazuto KatoDepartment of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan. kato@eth.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0001-9006-9551
The University of Osaka · JPNuffield Orthopaedic Centre · GBHiroshima University · JPUniversity of Oxford · GBHereditary Disease Foundation · US

Funding

Japan Science and Technology Corporation (JP), RISTEX JPMJRX18B3Japan Society for the Promotion of Science JP15K15167Japan Society for the Promotion of Science JP17K19812Ministry of Health, Labour and Welfare H29-Nanchitou(Nan)-Ippan 029 and 20FC1052Ministry of Health, Labour and Welfare H29-Nanchitou(Nan)-Ippan-030 and 20FC1036
6 · The paper itself

Abstract

backgroundThe role of patients in medical research is changing, as more emphasis is being placed on patient involvement, and patient reported outcomes are increasingly contributing to clinical decision-making. Information and communication technology provides new opportunities for patients to actively become involved in research. These trends are particularly noticeable in Europe and the US, but less obvious in Japan. The aim of this study was to investigate the practice of active involvement of patients in medical research in Japan by utilizing a digital platform, and to analyze the outcomes to clarify what specific approaches could be put into practice.

methodsWe developed the RUDY JAPAN system, an ongoing rare disease medical research platform, in collaboration with the Rare and Undiagnosed Diseases Study (RUDY) project in the UK. After 2 years of preparation, RUDY JAPAN was launched in December 2017. Skeletal muscle channelopathies were initially selected as target diseases, and hereditary angioedema was subsequently added. Several approaches for active patient involvement were designed through patient-researcher collaboration, namely the Steering Committee, questionnaire development, dynamic consent, and other communication strategies. We analyzed our practices and experiences focusing on how each approach affected and contributed to the research project.

resultsRUDY JAPAN has successfully involved patients in this research project in various ways. While not a part of the initial decision-making phase to launch the project, patients have increasingly been involved since then. A high level of patient involvement was achieved through the Steering Committee, a governance body that has made a major contribution to RUDY JAPAN, and the process of the questionnaire development. The creation of the Patient Network Forum, website and newsletter cultivated dialogue between patients and researchers. The registry itself allowed patient participation through data input and control of data usage through dynamic consent.

conclusionsWe believe the initial outcomes demonstrate the feasibility and utility of active patient involvement in Japan. The collaboration realized through RUDY JAPAN was enabled by digital technologies. It allowed busy patients and researchers to find the space to meet and work together for the Steering Committee, questionnaire development and various communication activities. While the practice of active patient involvement in Japan is still in its early stages, this research confirms its viability if the right conditions are in place. (331 words).

Indexed as

Dynamic consentInformation and communication technologyInformation technologyPatient-centered researchPatient involvementPatient reported outcome measuresRare diseases

Identifiers

PMID33526087
PMCPMC7852111
OpenAlexW3128923994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.